EBS Awarded $22.3M Contract Modification to Supply Anthrax Vaccine to U.S. Military

Emergent BioSolutions announced it has received a modification exercising an option period under an existing delivery order from the U.S. Department of War. The modification is for the supply of its BioThrax® (Anthrax Vaccine Adsorbed) and is valued at up to $22.3 million.

Key Details

• Order Value: The contract modification is valued at up to $22.3 million.
• Delivery Schedule: An initial delivery worth approximately $7.4 million will begin in 2026, with the remainder expected in 2027.
• Customer & Purpose: The order is from the U.S. Department of War to supply BioThrax® for use by all branches of the U.S. military as pre-exposure protection against anthrax disease.
• Contract Type: The order was issued under an existing indefinite-delivery/indefinite-quantity (IDIQ) contract with the U.S. government.